[go: up one dir, main page]

WO2010034105A8 - Hepatitis c inhibitor compounds - Google Patents

Hepatitis c inhibitor compounds Download PDF

Info

Publication number
WO2010034105A8
WO2010034105A8 PCT/CA2009/001237 CA2009001237W WO2010034105A8 WO 2010034105 A8 WO2010034105 A8 WO 2010034105A8 CA 2009001237 W CA2009001237 W CA 2009001237W WO 2010034105 A8 WO2010034105 A8 WO 2010034105A8
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
inhibitor compounds
analogs
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2009/001237
Other languages
French (fr)
Other versions
WO2010034105A1 (en
Inventor
Jeffrey O'meara
Josée BORDELEAU
Vida Gorys
Mélissa LEBLANC
Kirsten Lenhardt
Montse Llinas-Brunet
Mathieu Parisien
Marc-André Poupart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to EP09815517A priority Critical patent/EP2344487A4/en
Priority to CA2737958A priority patent/CA2737958A1/en
Priority to JP2011527161A priority patent/JP2012502925A/en
Publication of WO2010034105A1 publication Critical patent/WO2010034105A1/en
Publication of WO2010034105A8 publication Critical patent/WO2010034105A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compounds of Formula (I): wherein B, R3, L0, L1, R2, Rc and R1 are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection. In particular, the present invention provides novel peptide analogs, pharmaceutical compositions containing such analogs, and uses of these analogs in the treatment of HCV infection
PCT/CA2009/001237 2008-09-23 2009-09-14 Hepatitis c inhibitor compounds Ceased WO2010034105A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09815517A EP2344487A4 (en) 2008-09-23 2009-09-14 Hepatitis c inhibitor compounds
CA2737958A CA2737958A1 (en) 2008-09-23 2009-09-14 Hepatitis c inhibitor compounds
JP2011527161A JP2012502925A (en) 2008-09-23 2009-09-14 Hepatitis C inhibitor compound

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9929208P 2008-09-23 2008-09-23
US61/099,292 2008-09-23
US18663209P 2009-06-12 2009-06-12
US61/186,632 2009-06-12

Publications (2)

Publication Number Publication Date
WO2010034105A1 WO2010034105A1 (en) 2010-04-01
WO2010034105A8 true WO2010034105A8 (en) 2011-01-06

Family

ID=42059237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2009/001237 Ceased WO2010034105A1 (en) 2008-09-23 2009-09-14 Hepatitis c inhibitor compounds

Country Status (6)

Country Link
EP (1) EP2344487A4 (en)
JP (1) JP2012502925A (en)
AR (1) AR073659A1 (en)
CA (1) CA2737958A1 (en)
TW (1) TW201016694A (en)
WO (1) WO2010034105A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
KR20110075019A (en) * 2008-10-15 2011-07-05 인터뮨, 인크. Therapeutic Antiviral Peptides
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
MX2013007677A (en) 2010-12-30 2013-07-30 Abbvie Inc Macrocyclic hepatitis c serine protease inhibitors.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
SI2909205T1 (en) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CL2004001161A1 (en) * 2003-05-21 2005-04-08 Boehringer Ingelheim Int COMPOUNDS DESCRIBES COMPOUNDS DERIVED FROM QUINOLINA; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT AN ILLNESS CAUSED BY THE HEPATITIS C VIRUS.
US7514557B2 (en) * 2004-05-25 2009-04-07 Boehringer Ingelheim International Gmbh Process for preparing acyclic HCV protease inhibitors
CA2556669C (en) * 2004-06-28 2012-05-01 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
AP2009005073A0 (en) * 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
AP2874A (en) * 2007-06-29 2014-03-31 Gilead Sciences Inc Antiviral compounds
MX2010006210A (en) * 2007-12-05 2010-08-10 Enanta Pharm Inc Fluorinated tripeptide hcv serine protease inhibitors.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
AR073659A1 (en) 2010-11-24
EP2344487A1 (en) 2011-07-20
CA2737958A1 (en) 2010-04-01
TW201016694A (en) 2010-05-01
EP2344487A4 (en) 2012-03-21
WO2010034105A1 (en) 2010-04-01
JP2012502925A (en) 2012-02-02

Similar Documents

Publication Publication Date Title
WO2010034105A8 (en) Hepatitis c inhibitor compounds
MY164469A (en) Hcv ns3 protease inhibitors
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
UA83046C2 (en) Hepatitis c inhibitor compounds, pharmaceutical composition based thereon
EP1924593B8 (en) Hcv ns3 protease inhibitors
WO2008057995A3 (en) Hcv protease inhibitors
WO2008021927A3 (en) Hepatitis c virus inhibitors
MX2009009174A (en) Inhibitors of serine proteases for the treatment of hcv infections.
WO2008051477A3 (en) Hcv ns3 protease inhibitors
WO2006119061A3 (en) Hcv ns3 protease inhibitors
MY159958A (en) 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
ZA200900935B (en) Hepatitis C virus inhibitors
WO2007008657A3 (en) Hepatitis c virus inhibitors
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
IL198741A0 (en) Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof
NO20091845L (en) Macrocyclic peptides such as hepatitis C virus inhibitors
MX2011009644A (en) Hepatitis c virus inhibitors.
BR112012011100A2 (en) hepatitis virus inhibitor compounds, composition and use thereof
WO2008057871A3 (en) Inhibitors of hepatitis c virus
MX2011006631A (en) Hcv ns3 protease inhibitors.
WO2008057875A3 (en) Inhibitors of hepatitis c virus
WO2004032827A3 (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09815517

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase in:

Ref document number: 2011527161

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2737958

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009815517

Country of ref document: EP